This week Orthocell announced the appointment to two new US-based executives as the Company prepares to enter the US market with its nerve repair product, Remplirâ„¢.
Orthocell Chairman John Van Der Wielen spoke with Stockhead to discuss the Company’s strategic positioning ahead of its US market entry, sharing insights on why Remplir represents a compelling investment opportunity.
Here’s an excerpt:
“The difference between Orthocell is you’ve got a product that’s already been used in human bodies. There’s over $35 million of cash on the balance sheet, and it’s already in revenue with existing regulatory approval. It has crossed that threshold between this amazing concept and something that’s actually generating revenue… it’s a very low risk biotech compared to the majority of other smaller cap stocks. People are realising this is right on the threshold of coming into profit and significant growth.”